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Stromal regulation of cancer growth: A balancing act in surgeryThere are examples in the literature of dormant cancer cells
being stimulated after tissue injury.1–5 On the other hand, there
are also reports of cancer regression following injury.6–8 What
explanation can be offered for this discrepancy? The answer may
involve the stroma or connective tissue bed of solid tumour. Tradi-
tionally this stroma has been regarded mainly as a physical support
for the growing cancer cells. More recently, however, there is
evidence that stromal cells, many of which are immune cells,
may exude active growth control of cancer. For example, macro-
phages have been reported to produce many growth factors.9 These
cells can also produce collagen,10 can differentiate into ﬁbroblast-
like cells,11,12 and it has also been suggested that macrophages
can also transform into endothelial-like cells.13 The truly multifunc-
tional capacity of macrophages gives them the potential to play
a major role in tumour growth. In addition, other immune cells
such as T-cells and B-cells have been reported to produce growth
factors.14,15 Thus, stromal cell populations present in cancer tissue
can be engaged in opposing functions such as paracrine growth
regulation as well as the more traditional role of defense. A more
comprehensive name may be needed to reﬂect the dual role of
these stromal ‘immune’ cells. In fact, the reticulo-endothelial
system (RES) described by Aschoff16 over 80 years ago comes close.
Cancer develops with abnormal local growth of cells as well as
stroma in the parent organ. The next step is metastatic spread. It
is interesting to note that we found evidence that this metastatic
spread may involve macrophage/cancer cell units17 migrating
through the vascular system and establishing newgrowth at distant
sites. Formation of such units suggests that paracrine growth regu-
lation may occur at a very early stage of the metastatic process. At
the metastatic site, cancer cells are still dependent on the presence
of stroma for support and growth. End stage cancer, on the other
hand, can be composed of cells that are completely independent
of stromal regulation and can grow in the peritoneal or pleural
cavity as isolated cells.18 Using such cells for the study of solid
cancer growth regulation may not reﬂect the natural process.18
In the stromal dependent phase of tumour growth there is
a window of opportunity to control cancer by interfering with
this support. Examples are anti-angiogenic and anti-lymphagenic
treatment, reducing of growth factor output, disrupting physical
support, and increasing classical immunological activity, etc. Ulti-
mately, the goal of such treatments is stromal collapse.
An analogy may be drawn between this process and the shed-
ding of the endometrium during the menstrual cycle where
collagen producing cells (ﬁbroblast-like) during the follicular phase
can transform into phagocytic cells (macrophage-like) during the
menstrual phase.19 This process is hormonally controlled. Likewise,1743-9191/$ – see front matter  2009 Surgical Associates Ltd. Published by Elsevier Lt
doi:10.1016/j.ijsu.2009.01.003an infection can cause drastic changes within the tumour stroma;
enough to affect stromal support of cancer cells and initiate an
immunological reaction, resulting in regression of cancer.20
We reported on a case of apparent spontaneous regression of
pancreatic cancer which may serve as an example of such
phenomena.21 Brieﬂy, a 50-year-old male presented with a history
of weight loss, anorexia and discomfort after meals. Oncology
workup revealed pancreatic adenocarcinoma measuring
6.5 4 4-cm (T2N1M0). Ca19-9 level was slightly elevated. A
two-week regimen of radiotherapy combined with seven weeks
of gemcitabine failed to alter the progress of the disease. The
Ca19-9 level increased to 147 U/ml. The patient lost an additional
14-kg during this period and the treatmentwas considered a failure.
Two days after returning home, he developed acute abdominal pain
and was admitted to the hospital. Upon surgical examination, he
was found to have a perforated duodenal ulcer. Severe peritonitis
and fever followed his surgery. He subsequently developed pneu-
monia and recurrent high fevers. Despite a poor prognosis, after
a month of hospitalization and with considerable weight loss, the
patient was discharged to home care. Surprisingly, his recuperation
and weight gain was rapid. A subsequent PET scan was negative for
any focal disease and his tumour marker, Ca19-9, returned to the
normal range. An ultrasound, however, revealed residual tumour,
although it had regressed by approximately 70%. The patient
regained an essentially normal life with excellent health for about
a year, then he deteriorated and died 19 months following this
febrile infection. Although treatment other than his prolonged
infection may have contributed to his temporary regression, it
appears signiﬁcant that in this patient the duodenal perforation
occurred in the vicinity of the tumour. This could have facilitated
direct stimulation of the intra-tumoural stromal cell population.
Perhaps longer regression could have been obtained for this patient
by simulating his feverous infection through repeated booster inocu-
lations with a killed vaccine prepared from the organism(s) that
caused the peritoneal infection.
The duality of the effect of macrophages on tumour growth was
well illustrated in an experiment comparing inﬂuence of stimu-
lated and unstimulatedmacrophages on tumour growth. The inves-
tigators compared macrophages from normal and tumour-bearing
mice on the growth of experimental tumours (ﬁbrosarcoma, mela-
noma and lymphoma) in vivo. Both macrophage populations from
normal and tumour-bearing mice were found to stimulate tumour
growth. However, when an acute infection was mimicked through
exposure of macrophages to killed bacteria (Corynebacterium par-
vum) the same macrophage populations were able to inhibit
tumour growth in a dose dependent manner.22d. All rights reserved.
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suppurating sores following cancer surgery as a means of prevent-
ing recurrence. For example, the 19th century surgeon Verneuil
would leave the incision open or loosely approximated with
drainage, where suppurationwould then ensue.23 A student of Ver-
neuil stated that ‘‘I was often struck by the slowness with which
recurrence developed in such cases. I askedmyself if suppuration,
in eliminating the traces of cancer which had escaped the knife, did
not play a role in delaying recurrence, and if therein lay the secret of
success.’’24 A more prudent method was later recommended in
which a vaccine containing sterile bacteria would be injected into
the surgical site following tumour removal. For example, inModern
Operative Surgery25 (1943 edition), it was stated that following
surgery for sarcoma of the limbs ‘prophylactic injections of Coley’s
ﬂuid (a vaccine containing killed bacteria) should be given in doses
sufﬁcient to cause a sharp febrile reaction’. Such treatment with
a sterile ﬂuid containing a host of innate immune cell stimulators
such as endotoxins, lipopolysaccharides, streptokinase and
exotoxins (also known as superantigens) may be enough to shift
the balance from repair to defense (Fig.1), resulting in amore favor-
able post-surgical outcome.
This illustrates that the immune system may need to be chal-
lenged with factors it recognizes as both foreign and dangerous in
order to induce an optimal response. A real feverous infection
supplies both the foreign and dangerous components. How can we
mimic this without exposing the patient to such an infection?
Heat killed bacterial preparations may be useful as they can supply
the foreign component but they do not supply a danger signal.
However, coupling this vaccinewith surgical procedures can poten-
tially initiate an effective immune response against cancer. The
combination of the two procedures exposes the intra-tumoural
stromal cell population to a danger signal indicated by cellular
death caused by the surgery and to a foreign component provided
by the vaccine.
This is depicted in Fig. 1 by an increase in the defensive arm of
the immune system. On the other hand, during cancer surgery
(sterile wounding) without the vaccine, there is no foreign compo-
nent and an increase in growth factor production from the stroma
will attempt to ‘heal the wound’, simultaneously promoting tumour
growth. This would stimulate the reparative arm. Additional
complications may arise when elective surgery, or any further
sterile injury on ‘cured’ cancer patients activates dormant cancer
cells as illustrated in the case of a 43-year-old male who had






Fig. 1. This model illustrates the normal activity of the immune system engaged in
repair of ‘self’ and defense against ‘foreign’ (solid lines). The relative balance of the
two arms determines tumour growth, stable disease or regression. Growing tumours
subvert stromal cells to produce growth factors for its own beneﬁt by providing signals
that mimic a continual wound healing process. This induces the reparative arm. Sterile
surgical procedures can exacerbate this condition causing accelerated growth. An
exogenous agent such as Coley’s ﬂuid can shift the balance to the defensive arm
opposing this effect.minor accidental injury.26 Presently, we cannot differentiate
between former cancer patients that are really cured and those
that have no evidence of disease, but carry dormant micrometasta-
ses. To be able to do this would be an important step forward.
The differential effects of chronic and acute infections on subse-
quent cancer development further exemplify the opposing
outcomes of repair or defense (Fig. 1). Chronic infections such as
human papilloma virus (HPV) where there is continuous wounding
without effective immune response, have been associated with an
increased cancer risk over the long term.8 In contrast, a history of
frequent acute infections, where there is an effective immune
response, have been associated with a reduced risk for subse-
quently developing cancer.8
The preceding examples illustrate that there is an extremely
delicate balance in the dynamics of the tissue microenvironment
as it relates to cancer, teetering precariously between growth
promotion (wound healing), stable disease (dormant cancer), and
cancer regression (stromal collapse and cellular cytotoxicity). This
area needs more attention quickly, as the implications are far-
reaching and signiﬁcant.
Cancer diagnosis, surgery, or any procedure that has the poten-
tial to create signiﬁcant sterile wounding should be treated with
caution. These include mammographic compression, tissue biopsy,
etc. These actions can stimulate the growth promoting (wound
healing) factors in the microenvironment. For premenopausal
women it may be advisable to perform such procedures after the
follicular phase (day 8–12) of the menstrual cycle, as this phase is
strongly growth promoting.27 Also, advice might be given to former
cancer patients to stay clear of work that has a high risk for physical
injury, particularly compression injuries, such as may occur in
logging, construction, etc. or, in choosing elective surgery. If such
injuries do occur, immune systemmodifying agents may be admin-
istered during the recovery phase to minimize the risk of recur-
rence. There are also other issues to consider for cancer patients
such as the use of anti-pyretics and prophylactic antibiotics since
these agents will suppress immune system activation.
At the present time we do not advocate but rather discourage
making any drastic changes to established diagnostic and surgical
procedures. However, we believe it is timely and necessary to start
discussing the issues presented here. It is understandable some
may not receive this with enthusiasm as it is engraved in our
medical psyche that infections and fevers should be avoided. In
fact, such ideas may be viewed as a step backward in surgical prog-
ress. Indeed, a step backwards is sometimes needed to obtain
a broader prospective.
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